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Control of vascular responsiveness during human pregnancy
NORMAN F. GANT, RICHARD J. WORLEY, R0YIcE B. EVERETT, and PAUL C. MACDONALD
The Department of Obstetrics and Gynecology and the Cecil H. and Ida Green Center for Reproductive Biology
Sciences, University of Texas Health Science Center, Dallas, Texas
Over 40 years ago, Dieckmann and Michel re-
ported that vascular reactivity to the pressor effects
of a vasoactive agent (crude vasopressin) is greater
in preeclamptic than in normotensive pregnant
women [1]. In 1956, Raab et al found similar re-
sponses to the infusion of catecholamines [2]. Nei-
ther of these groups of investigators found a signifi-
cant difference in the pressor response between
nonpregnant subjects and normal pregnant con-
trols. In 1961, however, Abdul-Karim and Assali
found that the pressor response to a standard dose
of angiotensin II (All) late in normal pregnancy was
much less than that observed after delivery; that is,
the pregnant women were relatively refractory to
the pressor effects of infused All [3]. In 1968, Ta!-
ledo, Chesley, and Zuspan reported that pre-
eclamptic women were as sensitive to All as were
nonpregnant subjects. The preeclamptic subjects
appeared to have lost their pregnancy-associated
refractoriness to All [4]. These authors conjectured
that the relative refractoriness to All that occurred
in normal pregnancy might be the consequence of
an elevated plasma concentration of All. Notably, a
similar refractoriness to the pressor effects of inject-
ed All is exhibited by patients with secondary al-
dosteronism and in patients with congestive heart
failure or cirrhosis with ascites [5, 6].
In 1964, Kaplan and Silah observed that patients
with suspected low renin activity had increased sen-
sitivity to infused All [7]. They studied a variety of
normal and hypertensive men and nonpregnant
women by measuring the amount of All required to
increase the diastolic blood pressure 20 mm Hg, an
amount that will hereafter be called the "effective
pressor dose of All" (EPD-AII). Kaplan and Silah
found that a mean of 7.4 ng of All per kilogram of
body weight per minute of infusion was required to
elicit this response in control subjects. From an
analysis of their results, the authors proposed that
subjects with presumably low levels of endogenous
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All are more sensitive to the pressor effects of ex-
ogenous All than are those with presumably high
levels. That is, the EPD-All is significantly higher
in the latter group than it is in the former. In 1972,
Chinn and Dusterdieck correlated the plasma con-
centration of endogenous All with the EPD-AII and
were able to confirm that a proportionate relation-
ship exists between the two in nonpregnant subjects
[8].
Normal pregnant women develop an altered re-
sponse to the pressor effects of infused All [3, 9,
10]; this refractoriness to All is lost, however, dur-
ing pregnancies that are complicated by pregnancy-
induced hypertension [PIH] [9, 10]. Moreover, as
early as the 23rd week of gestation, an augmented
pressor response to All infusion is observed in
pregnant women who are normotensive but who are
destined to develop PIH [10] (Fig. 1). To elucidate
the nature of the difference in the pressor responses
to All infusions between those pregnant women
who remain normal and those who later develop
PIH, Gant et al [II] studied the EPD-AII before and
after rapid plasma volume expansion in normal
pregnant women. Volume expansion was effected
by the rapid i.v. infusion of solutions of normal sa-
line or 6% dextran. From an analysis of the results
obtained in this study, it was concluded that in late
human pregnancy, neither endogenous All plasma
levels nor plasma volume deficits are the principal
determinants of the blunted All pressor response
characteristic of normal human pregnancy. This
concept gained further support from the results of
the studies of Cunningham, Cox, and Gant [12],
who found that pregnant women who underwent
rapid blood volume expansion with infusions of
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Fig. 1. Comparison of the angiotensin II (All) doses required to evoke a pressor response in 120 primigravidas who remained norm oten-
sive and in 72 prirnigravidas who ultimatley developed pregnancy-induced hypertension. The nonpregnant mean is shown as a broken
line. The horizontal bars represent the SCM. The black circles represent the results in 120 subjects who remained normal (769 infusions).
The open circles represent the results obtained in 72 women who developed pregnancy-induced hypertension (421 infusions). The
difference between the two groups became significant after 22 weeks' gestation (P < 0.01), and the two groups continued to diverge
widely after 26 weeks' gestation (P < 0.001). (Reprinted with permission of J Clin Invest [10])
8
4
high hematocrit blood (a volume expansion that is
maintained over a long period of time) also experi-
enced no change in the amount of All required to
elicit a 20-mm-Hg rise in their diastolic blood pres-
sure. Based on these observations, it appears likely
that the impeded pressor response to All infusions
that accompanies normal pregnancy is the result of
increased vascular smooth muscle refractoriness to
Au. in women with PIH and in those gravidas des-
tined to develop PIH, the normal pregnancy-associ-
ated refractoriness to All pressor effects is lost.
In consideration of the above studies, a critical
question arises. What causes the vascular refractor-
iness to All that accompanies normal human preg-
nancy? McGiff and Itskovitz have shown that pro 5-
taglandins are potent mediators of vascular reactiv-
ity in several different organs under a variety of
conditions [13]. Moreover, Terragno and Terragno
reported that late in canine pregnancy, uterine
blood flow is related to the concentration of prosta-
glandin E (PGE) in uterine venous blood [14]. These
investigators also observed that the i.v. infusion of
All into pregnant dogs led to an increase in uterine
blood flow and rise in the concentration of PGE in
uterine venous blood. Conversely, when prosta-
glandin synthesis was inhibited by indomethacin
treatment, a decrease in uterine blood flow and a
decrease in the uterine venous concentration of
POE was observed. In studies of pregnant mon-
keys, Franklin et al found that intraarterial in-
fusions of All were followed by an increase in the
concentration of PGE in uterine venous blood,
whereas following indomethacin pretreatment, no
such increase occurred [15]. Vane reported a direct
relationship between prostaglandin efflux from the
kidney and renal blood flow [16]. Additionally,
when prostaglandin synthesis was inhibited by in-
domethacin treatment in this same study, renal
blood flow decreased. From results of studies in the
pregnant rabbit, Venuto et al concluded that uterine
venous blood PGE concentration was directly pro-
portional to uterine blood flow, because indometha-
cm treatment was associated with a fall in both uter-
ine blood flow and the concentration of PGE in uter-
ine venous blood [17].
From a consideration of these reports, it seemed
likely that prostaglandins or prostaglandin-related
substances might be involved in the regulation of
vascular reactivity during human pregnancy. To
test this hypothesis, we measured the effect of pros-
taglandin synthetase inhibitors on the EPD-AII in
normal pregnant women after the 28th week of
pregnancy. The volunteers for this study were ob-
tained from the inpatient hospital population of the
Obstetrics Service of Parkiand Memorial Hospital.
Each woman had been normotensive throughout
pregnancy, had no history of hypertension and ate
food of her choice from the hospital menu.
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After establishing the EPD-AII before treatment,
each subject was given either 25 mg of indometha-
cm (Indocin, Merck Sharp and Dohme) or 10 grains
of aspirin at 6-hour intervals. Two hours after the
second dose of indomethacin or aspirin, the EPD-
All was measured again. The patients engaged in
usual hospital activities between sets of All in-
fusions. No diet restrictions were imposed, and the
patients were not receiving cardiovascular medica-
tions or other drugs known to affect prostaglandin
production.
Eleven pregnant women were studied before and
after the administration of 25 mg of indomethacin
on two occasions (6-hour dose interval). In each
subject, the EPD-AII decreased after indomethacin
administration. Among these 11 subjects, the mean
EPD-AII before the administration of indomethacin
was 20.2 3.8 nglkg/min (mean sEM), a value sig-
nificantly greater than that observed after indo-
methacin treatment, 7.9 1.2 ng/kglmin (P <
0.005). The results of this study are depicted graph-
ically in Fig. 2 [18].
A similar decrease in the EPD-AII occurred fol-
lowing aspirin treatment in three women. The
EPD-AII after aspirin, 14.1 2.9 nglkglmin, was
significantly less than it was before the drug,
30.0 1.2 ng/kg/min (P < 0.01). When the re-
sults obtained with either prostaglandin synthe-
tase inhibitor, indomethacin or aspirin, are com-
bined, the EDP-AII before treatment, 22.7 3.4
ng!kglmin, was significantly greater than that after
treatment, 8.7 1.2 ng/kg/min (P <0.001) [18].
Thus, the administration of the prostaglandin
synthetase inhibitors, indomethacin and aspirin, to
normal pregnant women leads to a significant reduc-
tion in the amount of infused All required to evoke
a 20-mm-Hg rise in the diastolic blood pressure. Al-
though it is possible that aspirin and indomethacin
might decrease endogenous plasma renin activity in
these pregnant women and thereby alter vascular
reactivity to infused All, rapid plasma volume ex-
pansion, which has been shown to decrease plasma
renin activity, did not alter vascular reactivity in
normal pregnant women [11, 12]. Therefore, these
results are consistent with the concept that during
normal human pregnancy, prostaglandin(s) or pros-
taglandin-related substance(s) play an important
role in the development and maintenance of relative
vascular refractoriness to the pressor effects of All.
Thus, it is likely that the refractoriness to All usual-
ly observed during normal pregnancy may be medi-
ated in part by the action of prostaglandins or re-
lated substances that are produced in situ in the ar-
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Fig. 2. Mean effective fr' 'r dose of All before and during in-
domethacin treatment 1 II a rmotensive women studied during
late gestation.
terioles. Decreases in the rate of prostaglandin
synthesis or increases in the rate of prostaglandin
catabolism could result in an increased vascular re-
sponsiveness to infused All, a characteristic of the
pregnant woman who has developed, or is destined
to develop, PIH.
Other factors also appear to participate in modu-
lating vascular responsiveness to All during preg-
nancy. We have observed on many occasions that
normal pregnant women lose pregnancy-acquired
vascular refractoriness to All within 15 to 30 mm
after the placenta is delivered (Gant NF, unpub-
lished observations). From these observations, it
follows that a rapidly cleared substance of placental
origin might also promote refractoriness to the
pressor effects of All. Among rapidly cleared hor-
mones of placental origin, progesterone, or a me-
tabolite thereof, seemed a likely candidate for this
role. This apparent mediator of uterine quiescence
could also conceivably promote vascular smooth
muscle relaxation. Indeed, the i.m. administration
of large amounts of progesterone to the mother dur-
ing the latter stages of labor delays the loss of re-
fractoriness to All that follows delivery (Gant NF,
Worley RJ, and Chand 5, unpublished observa-
tions). The i.v. administration of progesterone does
not, however, restore All refractoriness to women
with PIH. Thus, it is possible that a progesterone
metabolite, formed in a significant amount after i.m.
administration of the hormone, might be respon-
sible for delaying the puerperal loss of vascular re-
fractoriness to the pressor effects of All. In earlier
studies, it was discovered that the plasma concen-
tration of 5a-pregnane-3,20-dione (5a-dihydropro-
gesterone [5a-DHP]) was strikingly elevated during
256
0
"a,
'a,0
a,0
-'a
0
0
>
uJ
P Ia ama
eon trol
Steroid infusion
Gant et al
Fig. 3. Effect of intravenously infused progesterone (15 pg per
minute) and 5a-dihydroprogesterone (12 pg per minute) on the
amount of administered All required to elicit a standard pressor
response in women with mild pregnancy-induced hypertension.
The effective pressor dose of All required at all time periods
during 5a-DHP infusion was significantly greater (P <0.001)
than that required before infusion of this steriod. The infusion
of progesterone was not associated with a change in the effective
pressor dose of All. (Reprinted with permission of Am J
Obstet Gynecol [19])
human pregnancy and that this progestin appears to
be derived from secreted progesterone [19].
The infusion of 5a-DHP into seven All-sensitive
women with mild PIH restored the vascular refrac-
toriness to All (Fig. 3) [19]. The mechanism where-
by this effect occurs is not known, but the infusion
of the hormone in five normal pregnant women who
had been rendered All-sensitive by the administra-
tion of indomethacin also restored vascular refrac-
toriness to All (Fig. 4). Thus, a progestin mecha-
nism may modulate the expression of prostaglan-
din-mediated vascular responsiveness to the
pressor effects of All in normal pregnancy. Alterna-
tively, this steroid may act independently of prosta-
glandin action.
Another recent observation adds further informa-
tion about the physiologic model of vascular re-
sponsiveness to angiotensin. The administration of
theophylline to seven All-sensitive women with
mild PIH in late pregnancy more than doubled the
mean EPD-AII, restoring the vascular refractor-
iness characteristic of normal pregnancy (Fig. 5)
[20]. Whether this treatment may be of therapeutic
benefit in lowering blood pressure could not be con-
cluded from this study because the mildly pre-
eclamptic women had become normotensive at bed
rest before the study was done. it is likely that this
effect of theophylline results from its inhibition of
the enzyme phosphodiesterase, a principal regula-
tor of intracellular cyclic nucleotide accumulation.
The inhibition of phosphodiesterase activity would
promote cyclic AMP accumulation within vascular
smooth muscle. An increase in cyclic AMP within
the myocyte would lead to sequestration of calcium
in cellular membranes. The resultant decrease in in-
tracellular free calcium ion concentration is general-
ly felt to promote smooth muscle relaxation (Fig. 6).
The results of all three of these recent investiga-
tions are consistent with the view that: (1) the rela-
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Fig. 4. Effect of5a-dihydroprogesterone infusions on the amount of All required to elicit a standard pressor response in indomethacin-
treated normal pregnant women. The amounts of All required to raise the diastolic pressure by 20 mm Hg before indomethacin treat-
ment, after indomethacin treatment, and during the infusion of ether-treated plasma and plasma containing 5a-DHP after indomethacin
treatment are illustrated. (Reprinted with permission of Am J Obstet Gynecol [19])
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woman ingests agents that are known to inhibit the
prostaglandin synthetase complex. The use of pros-
taglandin synthetase inhibitors, for example, indo-
methacin or aspirin, in attempts to prevent or arrest
premature labor could prove hazardous to the fetus,
not only through premature closure of the ductus
arteriosus but also through an increase in the mater-
nal vascular response to pressor agents. It is con-
ceivable that the increase in vascular responsive-
ness to All induced by prostaglandin synthetase in-
hibitors could result in significant maternal
_____ _____
vasoconstriction, although Zuckerman, in his study
of the ability of indomethacin to inhibit labor, did
not encounter hypertension in the intrapartum re-
cipients of the drug [21]. The response to these
agents might be especially hazardous, though, if the
patient is already sensitive to All, as in the case of
those who are destined to develop PIH.
Conclusion
Several important conclusions from these investi-
gations of pressor response to All are worth
reemphasizing. The normal pregnant woman devel-
ops vascular refractoriness to the pressor effects of
All (and other vasoactive agents). This vascular re-
fractoriness is principally the consequence of de-
creased vascular smooth muscle responsiveness to
All rather than the consequence of altered blood
volume or All plasma concentration. These preg-
nancy-induced changes in vascular responsiveness
to All are in contrast to the nonpregnant subject,
whose plasma concentrations of renin and/or All
are inversely proportional to vascular reactivity to
All. The mechanism that controls vascular refrac-
toriness during normal pregnancy likely involves a
localized prostaglandin action mediated through cy-
clic nucleotides. The action of progesterone or one
of its metabolites probably mediates the synthesis
Adenyl cyclase PG
ATP
: Phosphodiesterase
35' cychc AMP
—k-- AM P
Free Ca Bound Ca
Fig. 6. Schematic model of the proposed role of prostag/andin and cyclic 3',5'-adenosine monophosphate in pregnancy-associated
vascular refractoriness to the pressor effects of At!. (Reprinted with permission of Am J Obstet Gynecol [20])
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Fig. 5. Mean effective dose of A!! before and during theophylline
treatment of seven women with pregnancy-induced hyper-
tension. (Reprinted with permission of Am J Obstet Gynecol
[20])
tive vascular refractoriness to All that character-
izes normal pregnancy results from the action of a
prostaglandin(s) or a prostaglandin-related sub-
stance(s) on vascular smooth muscle; (2) the prosta-
glandin effect may be modified, or modulated, by
progestin action; and (3) the mechanism whereby
prostaglandin(s) (and perhaps progestins) alter vas-
cular sensitivity to All is probably mediated by the
cyclic nucleotide system in vascular smooth
muscle.
It is apparent from a consideration of the studies
discussed above that vascular reactivity to the
pressor effects of All can be manipulated readily. If
the loss of vascular refractoriness to All plays a
central role in the pathogenesis of PIH, it is possible
that a simple, fruitful means of restoring All refrac-
toriness, or preventing its loss altogether, will be
found some day.
It is also apparent from the above observations
that a potential hazard may exist when the pregnant
1
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or the catabolism of locally produced prostaglan-
dins or prostaglandin-like agents; however, a direct
effect of progestins on vascular smooth muscle can-
not be excluded at present. Disturbances in any of
these components of the mechanism could lead to
the loss of refractoriness to All and ultimately to
the development of PIH.
Women who develop PIH begin losing All refrac-
toriness as early as 18 weeks before hypertension
develops. The identification of this patho-
physiologic process between the 28th and 32nd
weeks of pregnancy provides the potential to pre-
dict the likelihood that hypertension will ensue.
From an awareness of the prolonged, preclinical
events that lead to PIH, it is evident that once hy-
pertension is detected, the disease is already ad-
vanced, at least in a temporal sense.
Sum,nary. Normal human pregnancy is charac-
terized by vascular refractoriness to All. This preg-
nancy-induced vascular refractoriness appears to
be mediated principally by decreased vascular
smooth muscle responsiveness to All rather than
by alterations in blood volume or plasma con-
centrations of renin or All. The mechanism
that controls vascular refractoriness during normal
pregnancy likely involves a localized prostaglandin
or prostaglandin-like action mediated through cy-
clic nucleotides. The action of progesterone or
one of its metabolites appears to mediate the
synthesis or the catabolism of locally produced
prostaglandins or prostaglandin-like agents.
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